GANX GAIN THERAPEUTICS INC Product Launches 8-K Filing 2024 - Announcement of Phase 1 study completion Gain Therapeutics, Inc. announced the completion of dosing in the multiple ascending dose (MAD) of its Phase 1 study of GT-02287, a novel small molecule therapy for Parkinson's Disease.Get access to all SEC 8-K filings of the GAIN THERAPEUTICS INC